For the quarter, revenue increased by 32.8% year-on-year, reaching ₹1,003.4 crore, up from ₹755.6 crore, marking the company’s first quarterly revenue exceeding ₹1,000 crore. Revenue also grew by 6.5% sequentially. Dollar revenue rose by 25.6% compared to the previous year, totaling $109.7 million.
EBITDA for the March quarter increased by 10.9% to ₹163.6 crore, compared to ₹147.5 crore during the same period last year. The EBITDA margin for the quarter was 16.3%, down from 19.5% a year earlier.
Also Read: Indegene CFO Suhas Prabhu mentions margin decline due to one-time M&A costs, anticipates a recovery soon
Adjusted EBITDA for the quarter reached ₹188.9 crore, marking a 23.2% year-on-year increase and a 5.4% rise sequentially. The adjusted EBITDA margin for the fourth quarter stood at 18.8%.
The company reported robust bookings in the quarter, securing one deal with an annual contract value (ACV) exceeding $3 million and seven additional deals in the $1–3 million range.
For the full fiscal year FY26, Indegene’s revenue totaled ₹3,510.5 crore, reflecting a year-on-year growth of 23.6% and surpassing the ₹3,500 crore annual revenue mark. In dollar terms, full-year revenue increased by 18.2% to $396.9 million. Adjusted EBITDA for FY26 was ₹679.3 crore, up 20.8% year-on-year, with a margin of 19.4%.
Also Read: Indegene Q3 results: Revenue rises 31% to ₹942 crore, while profit and margins decline
Cash flow from operations for the year grew by 47.3% year-on-year, reaching ₹650.8 crore, indicative of improved operational performance and solid business fundamentals.
The board of directors has proposed a final dividend of ₹2.25 per equity share of face value ₹2 each for the financial year ending March 31, 2026. This proposed final dividend will be distributed within 30 days of shareholder approval at the forthcoming annual general meeting. The record date to determine eligible shareholders and the date of the AGM will be announced separately.
Manish Gupta, Chairman and CEO of Indegene, stated, “FY26 was a landmark year for Indegene. We achieved over ₹1,000 crore in quarterly revenue for the first time, and ₹3,500 crore for the complete fiscal year.
Also Read: Indegene Q1 net profit increases by 33% due to higher revenue and margins
This highlights the strategic depth of our largest client relationships, with 53 clients generating over $1M in annual revenue, in addition to significant GenAI-driven successes across Commercial and Medical sectors. With a strong pipeline and an industry-leading revenue per employee of $75k, we aim to sustain this momentum in FY27.”
Indegene Ltd’s shares closed at ₹497.70, declining by ₹2.05, or 0.41%, on the BSE.
